57.89 % to Target, B. Riley FBR Maintains ‘”Buy”’ Rating on Iovance Biotherapeutics (IOVA) Shares Today

May 11, 2018 - By Ellis Scott

Iovance Biotherapeutics (IOVA) Rating Reaffirmed

Analysts at B. Riley FBR now has a $24 target price per share on Iovance Biotherapeutics (IOVA). B. Riley FBR and their recent target price per share would suggest a potential upside of 57.89 % from the company’s stock close price. The rating has been disclosed to clients in a research report on Friday morning.

Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) Ratings Coverage

Among 5 analysts covering Iovance Biotherapeutics Inc (IOVA), 5 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. Iovance Biotherapeutics Inc has $23.0 highest and $13.0 lowest target. $22.25’s average target is 46.38% above currents $15.2 stock price. Iovance Biotherapeutics Inc had 18 analyst reports since December 13, 2017 according to SRatingsIntel. The stock of Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) earned “Buy” rating by H.C. Wainwright on Thursday, December 14. Oppenheimer maintained the shares of IOVA in report on Tuesday, January 30 with “Buy” rating. The firm earned “Buy” rating on Tuesday, April 10 by B. Riley & Co. The stock has “Buy” rating by Oppenheimer on Tuesday, March 13. The rating was upgraded by FBR Capital to “Buy” on Tuesday, April 10. The stock of Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) earned “Buy” rating by Oppenheimer on Wednesday, January 24. FBR Capital maintained Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) on Thursday, January 25 with “Buy” rating. The stock of Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) earned “Buy” rating by FBR Capital on Wednesday, December 13. B. Riley & Co downgraded the stock to “Neutral” rating in Friday, February 23 report. The firm has “Buy” rating given on Monday, January 29 by Wells Fargo.

The stock increased 2.36% or $0.35 during the last trading session, reaching $15.2. About 659,455 shares traded. Iovance Biotherapeutics, Inc. (IOVA) has risen 116.45% since May 12, 2017 and is uptrending. It has outperformed by 104.90% the S&P500.

Iovance Biotherapeutics, Inc., a clinical-stage biotechnology company, focuses on developing and commercializing cancer immunotherapy products to harness the power of a patient's immune system to eradicate cancer cells. The company has market cap of $1.36 billion. The companyÂ’s lead product candidate is LN-144, an adoptive cell therapy that is in Phase II clinical trial using tumor-infiltrating lymphocytes , which are T cells derived from patientsÂ’ tumors for the treatment of patients with refractory metastatic melanoma. It currently has negative earnings. It is also developing LN-145 to treat cervical and head and neck cancers.

More news for Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) were recently published by: Nasdaq.com, which released: “Iovance Biotherapeutics to Present at Two Upcoming Investor Conferences in May” on May 02, 2018. Bizjournals.com‘s article titled: “New HQ puts Tampa immunotherapy company in Moffitt’s backyard” and published on May 03, 2018 is yet another important article.

Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) Ratings Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.